Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore Sells 9,203 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX) CEO Massimo Calafiore sold 9,203 shares of Orthofix Medical stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $17.14, for a total value of $157,739.42. Following the transaction, the chief executive officer now directly owns 124,151 shares in the company, valued at $2,127,948.14. The trade was a 6.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Massimo Calafiore also recently made the following trade(s):

• On Friday, January 10th, Massimo Calafiore sold 10,078 shares of Orthofix Medical stock. The shares were sold at an average price of $16.83, for a total value of $169,612.74.

Orthofix Medical Stock Up 0.8 %

Shares of NASDAQ:OFIX opened at $17.51 on Wednesday. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The business’s 50-day moving average is $18.17 and its 200-day moving average is $16.72. The company has a market capitalization of $669.13 million, a price-to-earnings ratio of -5.59 and a beta of 1.10.

Analyst Upgrades and Downgrades

OFIX has been the topic of several analyst reports. Stifel Nicolaus upgraded Orthofix Medical from a “hold” rating to a “buy” rating and upped their target price for the company from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm restated a “buy” rating and issued a $22.00 price target (up previously from $20.00) on shares of Orthofix Medical in a research report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $23.00.

Hedge Funds Weigh In On Orthofix Medical

Several institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. increased its stake in shares of Orthofix Medical by 480.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company’s stock valued at $1,318,000 after acquiring an additional 69,848 shares in the last quarter. Franklin Resources Inc. grew its holdings in Orthofix Medical by 37.4% in the third quarter. Franklin Resources Inc. now owns 20,960 shares of the medical device company’s stock worth $337,000 after purchasing an additional 5,702 shares during the period. Geode Capital Management LLC increased its stake in Orthofix Medical by 1.4% in the third quarter. Geode Capital Management LLC now owns 839,189 shares of the medical device company’s stock valued at $13,111,000 after purchasing an additional 11,559 shares in the last quarter. Barclays PLC raised its holdings in shares of Orthofix Medical by 38.8% during the third quarter. Barclays PLC now owns 122,472 shares of the medical device company’s stock valued at $1,912,000 after purchasing an additional 34,210 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of Orthofix Medical by 10.7% during the 3rd quarter. Jane Street Group LLC now owns 48,134 shares of the medical device company’s stock worth $752,000 after purchasing an additional 4,647 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.